These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 29665944)

  • 1. [Current Status and Challenges of CAR-T Immunotherapy in Hematologic Malignancies -Review].
    Cheng X; Wang YJ; Feng S; Wu YY; Yang TH; Lai X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Apr; 26(2):626-630. PubMed ID: 29665944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
    Allegra A; Innao V; Gerace D; Vaddinelli D; Musolino C
    Blood Cells Mol Dis; 2016 Nov; 62():49-63. PubMed ID: 27865176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gene-modified T-cell therapy using chimeric antigen receptors for pediatric hematologic malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2016 Jun; 57(6):701-8. PubMed ID: 27384848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
    Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
    Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New targets for CAR T therapy in hematologic malignancies.
    Savani M; Oluwole O; Dholaria B
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
    Hiramatsu H
    Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].
    Xu XJ; Zhao HZ; Tang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):521-5. PubMed ID: 23628068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
    Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
    Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
    Zhou SY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
    Davila ML; Bouhassira DC; Park JH; Curran KJ; Smith EL; Pegram HJ; Brentjens R
    Int J Hematol; 2014 Apr; 99(4):361-71. PubMed ID: 24311149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
    Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
    BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Application of CAR-T Cells in Haematological Malignancies.
    Skorka K; Ostapinska K; Malesa A; Giannopoulos K
    Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):34. PubMed ID: 33156409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Ho M; Zanwar S; Paludo J
    Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
    Freiwan A; Zoine JT; Crawford JC; Vaidya A; Schattgen SA; Myers JA; Patil SL; Khanlari M; Inaba H; Klco JM; Mullighan CG; Krenciute G; Chockley PJ; Naik S; Langfitt DM; Mamonkin M; Obeng EA; Thomas PG; Gottschalk S; Velasquez MP
    Blood; 2022 Dec; 140(25):2684-2696. PubMed ID: 35914226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.